Jingtao Gao, PhD, is the deputy director of the Managing Office of Clinical Center on TB, China CDC. She has been engaging in the field of TB prevention and control for 12 years. She obtained her master’s degree in internal medicine from Peking Union Medical University in 2008. She got her PhD in internal medicine from Beijing Tuberculosis and Thoracic Tumor Research Institute in 2015.

Jingtao Gao has worked at Keio University in Japan as an advanced visiting scholar from 2013-2015 on respiratory research. Her special interests include TB clinical practice, programmatic management and research activities on drug-resistant TB treatment. 

Jingtao Gao is the key member of China’s TB Clinical Trial Consortium (CTCTC), and is engaged in the planning, coordination and development of research activities of the consortium. In addition, she was involved in mentoring and supporting consortium investigators for research data management and manual writing.

Her practice and experience include over 10 national level TB scientific studies and projects, such as – The 11th-Five-Year National Science and Technology Major Project on drug resistance emergence mechanism and early warning model building, sponsored by the Ministry of Science and Technology of the People’s Republic of China (MOST). This was followed by – two 12th-Five-Year Projects on new treatment regimens for drug-resistant TB and efficacy of ultra-short course chemotherapy for newly diagnosed smear-positive drug-susceptible TB. She was designated as PI of the 13th-Five-Year Projects on exploring the mechanism of TB recurrence after treatment success of MDR-TB patients and also served as the Co-PI of Regional Prospective Observational Research in Tuberculosis (RePORT) which is a multi-country cohort study. For the last 3 years, she was designated as the director of the department of the clinical trial of Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing) responsible for protocol design, EDC development, data management and research quality control in several phase III-IV clinical trials of the new anti-TB drugs.